HDAC9 and intrahepatic cholangiocarcinoma: We further confirmed in vitro synergy with pemigatinib and another pan-HDAC inhibitor, panobinostat (Supplementary Fig. 3), suggesting broad applicability of pan-HDAC inhibitors with FGFR targeted therapies in FGFR2 fusion-positive ICC.